Picture of Elicera Therapeutics AB logo

ELIC Elicera Therapeutics AB Cashflow Statement

0.000.00%
se flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapMomentum Trap

Annual cashflow statement for Elicera Therapeutics AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.

2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:ARSARSARSARSARS
Standards:
SAS
SAS
SAS
SAS
SAS
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-2.83-13.1-19.4-17.1-16.9
Amortisation
Changes in Working Capital1.91-1.1910.82.16-6.59
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities-0.905-14.3-8.57-14.9-23.5
Capital Expenditures-0.059-0.001
Purchase of Fixed Assets
Other Investing Cash Flow Items0.05-0.00100.4840
Sale of Fixed Assets
Change in Net Investments
Cash from Investing Activities-0.009-0.00100.4830
Net Issuance / Retirement of Stock
Cash from Financing Activities12.455.10020.5
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash11.540.8-8.57-14.4-2.98